Literature DB >> 30108809

Synthesis and biological evaluation of N-alkyl naphthoimidazoles derived from β-lapachone against Trypanosoma cruzi bloodstream trypomastigotes.

Ari Miranda da Silva1,2, Leonardo Araújo-Silva1, Ana Cristina S Bombaça3, Rubem F S Menna-Barreto3, Claudio Eduardo Rodrigues-Santos1, Aurélio B Buarque Ferreira1, Solange L de Castro3.   

Abstract

The QSAR study of 34 2-aryl-naphthoimidazoles screened so far revealed that σi is the most important factor for their lytic activity on the bloodstream trypomastigote forms of T. cruzi, the etiologic agent of Chagas disease. Based on this result, 16 new N-alkyl-naphthoimidazoles derived from 6,6-dimethyl-3,4,5,6-tetrahydrobenzo[7,8]chromene[5,6-d]imidazole (the product of the reaction of β-lapachone with paraformaldehyde) by its reaction with halo-alkanes were prepared and evaluated against the parasite and peritoneal macrophages. The N1-n-hexyl and N3-n-hexyl naphthoimidazoles were 2.2 and 3.2 times more active than the standard drug benznidazole with selectivity indices of 2.7 and 13.4, respectively.

Entities:  

Year:  2017        PMID: 30108809      PMCID: PMC6071937          DOI: 10.1039/c7md00069c

Source DB:  PubMed          Journal:  Medchemcomm        ISSN: 2040-2503            Impact factor:   3.597


  41 in total

Review 1.  Investigation of DNA-binding properties of organic molecules using quantitative structure-activity relationship (QSAR) models.

Authors:  Rajeshwar P Verma; Corwin Hansch
Journal:  J Pharm Sci       Date:  2008-01       Impact factor: 3.534

2.  Trypanocidal activity of synthetic heterocyclic derivatives of active quinones from Tabebuia sp.

Authors:  A V Pinto; C N Pinto; M do C Pinto; R S Rita; C A Pezzella; S L de Castro
Journal:  Arzneimittelforschung       Date:  1997-01

3.  Structure-activity relationships in the effects of 1-alkylimidazoles on microsomal oxidation in vitro and in vivo.

Authors:  C F Wilkinson; K Hetnarski; G P Cantwell; F J Di Carlo
Journal:  Biochem Pharmacol       Date:  1974-09-01       Impact factor: 5.858

4.  VFV as a New Effective CYP51 Structure-Derived Drug Candidate for Chagas Disease and Visceral Leishmaniasis.

Authors:  Galina I Lepesheva; Tatiana Y Hargrove; Girish Rachakonda; Zdzislaw Wawrzak; Sébastien Pomel; Sandrine Cojean; Pius N Nde; W David Nes; Charles W Locuson; M Wade Calcutt; Michael R Waterman; J Scott Daniels; Philippe M Loiseau; Fernando Villalta
Journal:  J Infect Dis       Date:  2015-04-15       Impact factor: 5.226

5.  Imidazoles from nitroallylic acetates and α-bromonitroalkenes with amidines: synthesis and trypanocidal activity studies.

Authors:  Elumalai Gopi; Tarun Kumar; Rubem F S Menna-Barreto; Wagner O Valença; Eufrânio N da Silva Júnior; Irishi N N Namboothiri
Journal:  Org Biomol Chem       Date:  2015-10-14       Impact factor: 3.876

6.  Naphthoimidazoles promote different death phenotypes in Trypanosoma cruzi.

Authors:  R F S Menna-Barreto; J R Corrêa; C M Cascabulho; M C Fernandes; A V Pinto; M J Soares; S L De Castro
Journal:  Parasitology       Date:  2009-03-13       Impact factor: 3.234

7.  Chagas disease: a Latin American health problem becoming a world health problem.

Authors:  Gabriel A Schmunis; Zaida E Yadon
Journal:  Acta Trop       Date:  2009-11-20       Impact factor: 3.112

8.  1,3-Azoles from ortho-naphthoquinones: synthesis of aryl substituted imidazoles and oxazoles and their potent activity against Mycobacterium tuberculosis.

Authors:  Kelly C G Moura; Paula F Carneiro; Maria do Carmo F R Pinto; José A da Silva; Valéria R S Malta; Carlos A de Simone; Gleiston G Dias; Guilherme A M Jardim; Jéssica Cantos; Tatiane S Coelho; Pedro E Almeida da Silva; Eufrânio N da Silva
Journal:  Bioorg Med Chem       Date:  2012-08-31       Impact factor: 3.641

9.  Ketoconazole protects against infection with Trypanosoma cruzi in a murine model.

Authors:  R E McCabe; F G Araujo; J S Remington
Journal:  Am J Trop Med Hyg       Date:  1983-09       Impact factor: 2.345

10.  Economic crisis and increased immigrant mobility: new challenges in managing Chagas disease in Europe.

Authors:  Yves Jackson; Monica Varcher Herrera; Joaquim Gascon
Journal:  Bull World Health Organ       Date:  2014-09-09       Impact factor: 9.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.